Statin Combined With Amlodipine Treats Primary Aldosteronism
A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 180 participants.
Also called NCT06523465
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 180 participants
- Registry
-
NCT06523465
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06523465. Randomized; no masking; primary purpose treatment. Start 2024-09-10 (actual); primary completion 2026-11-15 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Statin Combined With Amlodipine Treats Primary Aldosteronism
- Acronym
- STOP-PA
- Condition
- Primary Aldosteronism
- Condition
- Statin
- Condition
- Hypertension
- Intervention (Drug)
- Simvastatin combined with Amlodipine besylate
- Intervention (Drug)
- Simvastatin combined with Spironolactone and Amlodipine besylate.
- Intervention (Drug)
- Amlodipine besylate combined Spironolactone
- Lead sponsor
- Third Military Medical University
Record details
- Record id
cardio:ct-nct06523465- Content hash
528568212685033cbf255616d463ad94f5719f040983268646b793d7a41f86f7